Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a China-based company mainly engaged in the research and development (R & D), as well as production of biomedicine in the fields of tumor, bleeding and blood diseases, liver and gallbladder diseases. The Company’s main technology platforms include precision small molecule drugs R & D and industrialization platform and complex recombinant protein drug development and industrialization platform. The Company’s R & D product pipelines include Donafenib, Recombinant human thrombin for topical use, Jaktinib hydrochloride tablets, Alkotinib, Recombinant human thyroid stimulating hormone for injection, Jaktinib hydrochloride cream, ZG5266, ZG0588, ZG170607, double Specific antibodies ZG005 and ZG006. The Company also provides R & D and clinical trial drug production and processing services. The Company operates its businesses primarily in Mainland China.